Teva Stock: 3 Key Things to Know
While shares of Teva have risen a modest 9% year to date, the company is trading at low valuation compared to many of its peers in the pharmaceutical industry. Its forward P/E is significantly lower than major players like Merck, Pfizer, and Mylan, but what specific topics should investors focus on when analyzing this investment today? In the following video, analyst Max Macaluso discusses three key issues on his radar: Teva's standing in the multiple sclerosis market and competition from companies including Biogen , rumors around a possible merger, and its leadership.
The Motley Fool's top stock of 2014
The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has just hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2014." To find out which stock it is and read our in-depth report, simply click here. It's free!
The article Teva Stock: 3 Key Things to Know originally appeared on Fool.com.Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.